Elora - My experience after 3 weeks

[Gohengrin]

Last week was good too. I think i will only write here, if my experience changes. But for now, its a good replacement for cagri. I stalled for months with reta/tirz and cagri and now I lost about 4 to 5kg last month since I started elora. I now under 100kg and it feels good

I think elora takes 2-3 weeks before it goes brooooom.

 

[ladyj779]

Does this means that elora will have to be continued as long as the person is taking triz (even in maintenance)? Or it is only a short term add on to break platueu etc?

Also, as the half life is much longer for elora, why is the dose frequency supposed to be the same as the weekly tirz?

For probably the same reason tirz and reta are weekly: adherence, rather than optimal efficacy. People generally are really bad at med compliance. If elora had some 10 or 12 or 15 day schedule, it would be messed up almost immediately by a lot of people...and by almost immediately, I mean by shot 2.

Again, why grey is great for some, but even very clear dr oversight doesn't work for others.

 

[HereKittyKitty]

Does this means that elora will have to be continued as long as the person is taking triz (even in maintenance)? Or it is only a short term add on to break platueu etc?

Also, as the half life is much longer for elora, why is the dose frequency supposed to be the same as the weekly tirz?

Well, GLP-1 is designed as a lifetime medication. Not sure about the Amlyn-targeted products. I don't want to guess.

 

[Grogu]

Well, GLP-1 is designed as a lifetime medication. Not sure about the Amlyn-targeted products. I don't want to guess.

It's probably the same for amylin agonists, in that these are likely lifetime medications because they treat obesity rather than cure it.

That said, the exciting thing about amylin is its demonstrated ability to restore leptin sensitivity in obese individuals, and leptin is the key long-term adipostat hormone. The important nuance is that obesity-related leptin dysfunction is not a shortage problem, obese individuals often have normal or even elevated leptin levels. The issue is that the body becomes less sensitive to it over time. Amylin appears to shift the leptin sensitivity threshold downward, restoring leptin functionality in key hypothalamic and hindbrain regions, and ultimately facilitating more durable weight loss.

Studies of weight maintenance also suggest that amylin coadministration helps people sustain their losses better than glp-1s alone. That, combined with its apparent ability to break through weight loss plateaus, is arguably where the real clinical promise lies.

 

[HereKittyKitty]

Thank you, @Grogu. This is informative and useful. You made me smarter today.

 

[TheAnonOne]

Im excited to get my hands on it. Breaking a stall is the whole reason I joined the forum. Basically just learning of eloralintide

 

[Grogu]

Thank you, @Grogu . This is informative and useful. You made me smarter today.

Thanks! The leptin sensitivity threshold aspect is definitely compelling. I got interested in leptin because I was trying to understand what it would actually take to reset someone's set point downward, and leptin regulation seems like a plausible pathway. Whether eloralintide or any amylin agonist can meaningfully accomplish that remains an open question.

To clarify my earlier point, the stronger human evidence for amylin coadministration is in active treatment, not maintenance specifically. The maintenance benefit I mentioned was drawn from preclinical data, so I should have been clearer about that distinction. Unfortunately, there aren't many robust clinical studies on what works best for maintenance… they've left us hanging in the wind on that one.

 

[Seasonal1]

Thanks! The leptin sensitivity threshold aspect is definitely compelling. I got interested in leptin because I was trying to understand what it would actually take to reset someone's set point downward, and leptin regulation seems like a plausible pathway. Whether eloralintide or any amylin agonist can meaningfully accomplish that remains an open question.

To clarify my earlier point, the stronger human evidence for amylin coadministration is in active treatment, not maintenance specifically. The maintenance benefit I mentioned was drawn from preclinical data, so I should have been clearer about that distinction. Unfortunately, there aren't many robust clinical studies on what works best for maintenance… they've left us hanging in the wind on that one.

Grogu, you are a king amongst all lab rats here. A lab rat's, lab rat. Our early innovator. Thanks for sharing your experience. I'm enjoying following along. Thanks...

 

[Seasonal1]

I read on Peppy's tonight that Elora is coming to BFF... It will be interesting to see if it tests out.

 

[Calm Logic]

Thanks! The leptin sensitivity threshold aspect is definitely compelling. I got interested in leptin because I was trying to understand what it would actually take to reset someone's set point downward, and leptin regulation seems like a plausible pathway. Whether eloralintide or any amylin agonist can meaningfully accomplish that remains an open question.

To clarify my earlier point, the stronger human evidence for amylin coadministration is in active treatment, not maintenance specifically. The maintenance benefit I mentioned was drawn from preclinical data, so I should have been clearer about that distinction. Unfortunately, there aren't many robust clinical studies on what works best for maintenance… they've left us hanging in the wind on that one.

Exactly, all up in the air. But with reta insomnia, you sleep less so you have more time to workout, haha. Reta bros for the indirect leptin win.

 

[Grogu]

Exactly, all up in the air. But with reta insomnia, you sleep less so you have more time to workout, haha. Reta bros for the indirect leptin win.

Yes, definintely all up in the air and scant research on amylin and leptin. I certainly didn’t want to overstate amylin agonists ability to regulate long-term weight. But as far as amylin agonists in general, there appears to be a lot of BP interest working this area. This table is from a recent paper published in Nature discussing recent pharmalogical developments in obesity treatment. The table lists of all the amylin agonists in development. I was suprised at the extent of the investment in this pathway. I’d like to think that there is more going on than just another appeptite suppressive medication. But that could be wishful thinking.

[Imported image pending local asset: attachments-img_0242-webp.36872]